Topical ophthalmic anti-allergy drugs are identified by the extent of their interaction with a phospholipid model membrane. Disclosed are topically administrable ophthalmic formulations containing amphipathic anti-allergy compounds at concentrations such that the drugs have Surface Activity Ratings from about 2-11. Provided the drug is not selected from the group consisting of olopatadine; ketotifen; emedastine; pheniramine; pyrilamine; cromolyn; nedocromil; and levocabastine.

The invention relates to the use of pharmaceutically acceptable solid salts containing cromoglicic acid and/or nedocromil as a vehicle at concentrations which are not therapeutically and prophylactically active in suspension aerosol formulations of pharmaceutical active ingredients. Use of said salts improves dispersion characteristics increases physical and chemical stability of active ingredients which are sensitive to moisture allows for accurate dosing especially of active ingredients even a...

A formulation for example an oil-in-water emulsion comprising an amphoteric surfactant alkoxylated cetyl alcohol and a polar drug. The drug may be sodium cromoglycate or nedocromil sodium. The formulation may be useful in the treatment of skin disease such as atopic dermatitis.

The present invention provides a pharmaceutical composition pharmaceutical product or kit comprising a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-13-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof and a second active ingredient (B) being disodium cromoglycate or nedocromil for use in the treatment of obstructive airways diseases.

Topical ophthalmic anti-allergy drugs are identified by the extent of their interaction with a phospholipid model membrane. Disclosed are topically administrable ophthalmic formulations containing amphipathic anti-allergy compounds at concentrations such that the drugs have Surface Activity Ratings from about 2-11. Provided the drug is not selected from the group consisting of olopatadine; ketotifen; emedastine; pheniramine; pyrilamine; cromolyn; nedocromil; and levocabastine.

Topical ophthalmic anti-allergy drugs are identified by the extent of their interaction with a phospholipid model membrane. Disclosed are topically administrable ophthalmic formulations containing amphipathic anti-allergy compounds at concentrations such that the drugs have Surface Activity Rating s from about 2-11. Provided the drug is not selected from the group consisting of olopatadine; ketotifen; emedastine; pheniramine; pyrilamine; cromolyn; nedocromil; and levocabastine.

The invention relates to the use of pharmaceutically acceptable solid salts containing cromoglicic acid and/or nedocromil as a vehicle at concentration s which are not therapeutically and prophylactically active in suspension aerosol formulations of pharmaceutical active ingredients. Use of said salts improves dispersion characteristics increases physical and chemical stabili ty of active ingredients which are sensitive to moisture allows for accurate dosing especially of active ingredients eve...

The invention relates to the use of pharmaceutically acceptable solid salts containing cromoglicic acid and/or nedocromil as a vehicle at concentrations which are not therapeutically and prophylactically active in suspension aerosol formulations of pharmaceutical active ingredients. Use of said salts improves dispersion characteristics increases physical and chemical stability of active ingredients which are sensitive to moisture allows for accurate dosing especially of active ingredients even a...

A formulation for example an oil-in-water emulsion comprising an amphoteric surfactant alkoxylated cetyl alcohol and a polar drug. The drug may be sodium cromoglycate or nedocromil sodium. The formulation may be useful in the treatment of skin disease such as atopic dermatitis.